GLP-1 Receptor Agonists

Phase 1Small molecule

GLP-1 Receptor Agonists is one of 53 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Ovary SyndromeActive, not recruiting

PCOSCompleted

LymphedemaRecruiting

Polycystic Ovary SyndromePreclinical

Active, not recruiting

PCOSPreclinical

Completed

LymphedemaPhase 1

Recruiting

Competition

Competitive Landscape

72 competitors in Polycystic Ovary Syndrome

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

6 2

Victoza

Novo Nordisk

Approved

4 3

Avandia

Jazz Pharmaceuticals

Approved

2 4

Daliresp

AstraZeneca

Approved

1 5

Evista

Meridia

1 7

Zocor

OOrganon and Co

Approved

1 8

Tradjenta

Boehringer Ingelheim

Approved

1 9

Gynorest

SSolvay Pharmaceuticals

Approved

1 10

Januvia

ZZydus Therapeutics Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Polycystic Ovarian Syndrome

NCT07169136

Q2 2027

Phase 1Recruiting

Lymphedema

NCT07012642

Q3 2027

Not yet recruiting

Type 2 Diabetes Mellitus

NCT07723820

Q4 2027

Not yet recruiting

Type 2 Diabetes

NCT07818226

Clinical

Trials by Indication[1]

PCOS1 trial

Research of Intensive Lifestyle Intervention for PCOS Patients With IGT

Completed·RRenJi Hospital·N/A·NCT02446834·40 enrolled

Lymphedema1 trial

Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

Recruiting·AAdvanced Reconstructive Surgery Alliance·Phase 1·NCT07012642·110 enrolled

Polycystic Ovarian Syndrome1 trial

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

Recruiting·NNemours Children's Clinic··NCT07169136·20 enrolled

Type 2 Diabetes1 trial

Prospective Evaluation of the Effects of GLP-1 Receptor Agonists on Salivary Physicochemical Parameters, Antimicrobial Peptide Levels, and Oral Health

Not yet recruiting·KKırıkkale University··NCT07818226·50 enrolled

Type 2 Diabetes Mellitus1 trial

Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Multimodal Retinal Imaging Cohort Study (the GLIDE Study)

Not yet recruiting·TThammasart University Hospital··NCT07723820·126 enrolled

4 more indications

Skin Aging1 trial

A Prospective Observational Study of Facial Aging in Identical Twins Using Three-Dimensional Imaging

Not yet recruiting·PPonsky Facial Aesthetics And Plastic Surgery, Llc··NCT07760532·200 enrolled

Short Bowel Syndrome (SBS)1 trial

Therapeutic Efficacy of GLP-1 on Intestinal Barrier Function in Patients With Short Bowel Syndrome and Intestinal Failure: A Preliminary Randomized Controlled Trial

Completed·JJinling Hospital, China·Preclinical·NCT07297238·20 enrolled

Diabetes1 trial

Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases

Recruiting·CCliniques universitaires Saint-Luc- Université Catholique de Louvain··NCT07703683·100 enrolled

Alzheimer disease1 trial

GLP-1 Receptor Agonists Prevent Alzheimer's Disease Onset, Not Progression: Resolving the Real-World-Randomised Trial Paradox Across Five Continents

Completed·WWest China Hospital··NCT07677865·213,891 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for GLP-1 Receptor Agonists. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP-1 Receptor Agonists compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP-1 Receptor Agonists. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jinling Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJinling Hospital, China

GLP-1 Receptor Agonists

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

PCOS1 trial

Lymphedema1 trial

Polycystic Ovarian Syndrome1 trial

Type 2 Diabetes1 trial

Type 2 Diabetes Mellitus1 trial

Skin Aging1 trial

Short Bowel Syndrome (SBS)1 trial

Diabetes1 trial

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News